Clinical Trial

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07359014
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Tongji Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Jinhua Municipal Central Hospital
Conditions Relapse Multiple Myeloma
Enrollment 25 participants
Start Date 2025-11-01
Primary Completion 2027-10-31 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-22